McKinsey identified that FIC will still have an impressive 40% market share after 10 years. What matters is being FIC, being second of fifth doesn’t really make a difference.
what would be more interesting would be to see this chart shown over the 10 years to see how it progressively drops from 100% to 40%. However, I think it’s safe to assume that throughout and even after the decade, there is still strong financial outcomes for a drug that is established FIC.
https://www.mckinsey.com/industries/life-sciences/our-insights/pharmas-first-to-market-advantage
some other benefits of bisantrene?
speciality drugs have a bigger advantage with maintaining and capitalizing on the market share.
ultimately, cardio toxicity has been known for a long time and we are at the front of the pack with a late stage, clinically safe and tolerable drug. Not a bad position imo
RAC media coverage, page-1118
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.045(3.14%) |
Mkt cap ! $248.8M | |||
| Open | High | Low | Value | Volume |
| $1.42 | $1.48 | $1.41 | $74.60K | 51.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6944 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 3096 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.47 |
Change
0.045 ( 1.69 %) |
||||
| Open | High | Low | Volume | ||
| $1.41 | $1.48 | $1.41 | 21844 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| RAC (ASX) Chart |